Biotech leaders are navigating disciplined growth, shifting global dynamics, and rising expectations across boards, partners, and clinical teams. In this opening episode, a panel of experienced biotech executives step back to discuss where the industry truly stands, the forces shaping decision‑making, and how leaders are approaching strategy, execution, and collaboration in today’s biotech landscape. Featuring: - Claire Riches, VP, Clinical Solutions, Citeline - Ross Pettit, Chief Development Officer, Kestrel Therapeutics - Carrie Melvin, Head of Clinical Operations and Data Management, Lantheus - Marrissa Volpe, SVP, Clinical Development, NervGen - Jennifer Burg, SVP, Clinical Development Operations, Axonis Therapeutics View the video series and find out more information here: https://www.citeline.com/biotech

The State of Play in Biotech and the Decisions Shaping the Industry

Citeline Podcasts

The one thing that has not changed in our industry is the percentage of participants that joins clinical trials. We have done nothing to educate the world on what it means, what it means to be a participant, why we do it, why we need them. We have not done that. Even before COVID, there was just a lot more money out there and people were getting money based on pre-clinical data and I think that's all significantly changed.

I think that discipline was very much anchored in AI, that we know it's going to help us but we've got to be very disciplined about where we apply it, how we use it, what we use the insights for that are generated. I'm open to it because I like technology and it doesn't take away the human piece of thinking, that critical thinking. Are we moving more to a commercialized model at the site level and if we are, is that a good thing?

You're dealing with one academic site very different to a commercial site so I think this commercialization is bringing a little bit more consistency. But you also have to be careful, right, because in my world clinical and commercial have to be somewhat separate so that there's not too much overlap in terms of swaying or bias. In Australia, you know, from a quality perspective is comparable to anywhere else but from a cost and speed perspective there's nowhere else that sort of competes on that same level.

We haven't changed the ways we've done things for the last 30 years as an industry and I think we've got to start challenging ourselves to do things a little differently. Thank you very much for joining us on today's podcast, Small Biotech's Big Decisions.

The State of Play in Biotech and the Decisions Shaping the Industry

Read the full transcript

The candid version is on a podcast,
not the earnings call.

The State of Play in Biotech and the Decisions Shaping the Industry

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.